These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36916985)

  • 1. Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes.
    Oiwa A; Hiwatashi D; Takeda T; Miyamoto T; Kawata I; Koinuma M; Yamazaki M; Komatsu M
    J Clin Endocrinol Metab; 2023 Aug; 108(9):2203-2210. PubMed ID: 36916985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
    Kato S; Maruyama S; Makino H; Wada J; Ogawa D; Uzu T; Araki H; Koya D; Kanasaki K; Oiso Y; Goto M; Nishiyama A; Kobori H; Imai E; Ando M; Matsuo S
    Clin Exp Nephrol; 2015 Dec; 19(6):1098-106. PubMed ID: 25795029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
    Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
    Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
    Bakris G; Yang YF; Pitt B
    Hypertension; 2020 Jul; 76(1):144-149. PubMed ID: 32520623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.
    Lindhardt M; Persson F; Oxlund C; Jacobsen IA; Zürbig P; Mischak H; Rossing P; Heerspink HJL
    Nephrol Dial Transplant; 2018 Feb; 33(2):296-303. PubMed ID: 28064163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
    Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
    Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
    Ding K; Li Z; Lu Y; Sun L
    Eur J Intern Med; 2023 Sep; 115():114-127. PubMed ID: 37328398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
    Gwoo S; Kim YN; Shin HS; Jung YS; Rim H
    Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S; Bigazzi R; Campese VM
    Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.